Explore

Trendline Trendline
New RNA-seq Technology CIPHER-seq Enhances Cancer Research by Simultaneously Quantifying RNA and Proteins

New RNA-seq Technology CIPHER-seq Enhances Cancer Research by Simultaneously Quantifying RNA and Proteins

New RNA-seq Technology CIPHER-seq Enhances Cancer Research by Simultaneously Quantifying RNA and Proteins
Trendline Trendline
Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development

Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development

Creatv Bio Opens CLIA-Certified Laboratory to Enhance Oncology Drug Development
Trendline Trendline
BostonGene and Hokkaido University Collaborate to Enhance Precision Oncology in Japan

BostonGene and Hokkaido University Collaborate to Enhance Precision Oncology in Japan

BostonGene and Hokkaido University Collaborate to Enhance Precision Oncology in Japan
Trendline Trendline
Innate Pharma Reports Q1 2026 Business Update and Financial Results

Innate Pharma Reports Q1 2026 Business Update and Financial Results

Innate Pharma Reports Q1 2026 Business Update and Financial Results
Rapid Read Rapid Read
New Drugs Target 'Zombie Cells' to Enhance Cancer and Aging Treatments

New Drugs Target 'Zombie Cells' to Enhance Cancer and Aging Treatments

Researchers at the MRC Laboratory of Medical Sciences and Imperial College London have identified a new strategy to eliminate senescent 'zombie' cells, which are linked to cancer and aging. These cells, which survive in a fragile state, produce a protective protein that prevents their death. By targeting this protein, researchers can induce self-destruction in these cells, potentially improving cancer treatments and therapies for age-related diseases. The study, published in Nature Cell Biology, highlights the potential of this approach to work alongside existing cancer therapies like chemotherapy.
Rapid Read Rapid Read
Stowers Institute Develops AI Model to Predict Cell Fate and Address Cancer

Stowers Institute Develops AI Model to Predict Cell Fate and Address Cancer

Researchers at the Stowers Institute of Medical Research have developed an AI model named RegVelo, which integrates gene-regulatory networks with single-cell biology to predict how cells change over time. This model, detailed in a study published in Cell, aims to bridge the gap between understanding cell state transitions and the gene regulatory networks that control these changes. The research highlights the model's application in zebrafish neural crest development, identifying key regulators of pigment cell formation. The model's predictions were validated using CRISPR/Cas9-mediated knockout and single-cell Perturb-seq, demonstrating its potential to generate biologically meaningful hypotheses. The study suggests that RegVelo's applications extend beyond neural crest cells, potentially impacting developmental biology and cancer treatment modeling.
Trendline Trendline
Caris Life Sciences Study Shows Whole Exome Sequencing Improves Cancer Treatment Outcomes

Caris Life Sciences Study Shows Whole Exome Sequencing Improves Cancer Treatment Outcomes

Caris Life Sciences Study Shows Whole Exome Sequencing Improves Cancer Treatment Outcomes
Rapid Read Rapid Read
Caris Life Sciences Study Shows Whole Exome Sequencing Improves Cancer Treatment Outcomes

Caris Life Sciences Study Shows Whole Exome Sequencing Improves Cancer Treatment Outcomes

Caris Life Sciences has published a study demonstrating that using Whole Exome Sequencing (WES) to measure tumor mutational burden (TMB) provides a more accurate prediction of the benefits of pembrolizumab immunotherapy compared to targeted gene panels. The study, published in Cancer Immunology, Immunotherapy, highlights that TMB is a crucial biomarker for determining patient eligibility for pembrolizumab, a cancer treatment. The research involved 26,756 patients and found that WES offers a comprehensive genomic profile, leading to better treatment outcomes. The study revealed that targeted gene panels miscalculate TMB in 10-15% of cases, potentially leading to incorrect treatment decisions.
Rapid Read Rapid Read
Phase 1 Trial Explores Personalized Neoantigen DNA Vaccine for Glioblastoma Patients

Phase 1 Trial Explores Personalized Neoantigen DNA Vaccine for Glioblastoma Patients

A phase 1 clinical trial is investigating the safety and effectiveness of a personalized neoantigen DNA vaccine, GNOS-PV01, for patients with newly diagnosed MGMT unmethylated glioblastoma multiforme (GBM). The trial involves nine participants who received the vaccine following surgical resection and radiotherapy. The study aims to assess the vaccine's safety, feasibility, and immunogenicity. The vaccine is designed to target specific neoantigens identified through whole-exome sequencing of tumor samples. Patients received intramuscular vaccinations combined with a DNA plasmid encoding interleukin-12 as a molecular adjuvant. The trial's primary endpoint is to determine the safety and feasibility of the vaccine, with secondary endpoints including progression-free survival and overall survival rates.
Trendline Trendline
AI and Biotechnology Convergence Drives Personalized Medicine Advancements

AI and Biotechnology Convergence Drives Personalized Medicine Advancements

AI and Biotechnology Convergence Drives Personalized Medicine Advancements
Rapid Read Rapid Read
AI-Driven Protein Design Revolutionizes Fluorescent Cell Imaging

AI-Driven Protein Design Revolutionizes Fluorescent Cell Imaging

A team led by HHMI Investigator David Baker and Janelia Senior Group Leader Luke Lavis is pioneering a new approach to fluorescent cell imaging using AI-designed proteins. This initiative, part of the AI@HHMI project, aims to create a new class of fluorescent imaging probes known as NovoTags. These probes are developed by combining AI-driven protein design with advanced fluorescent dyes, allowing researchers to visualize multiple proteins simultaneously within cells. The project leverages an AI model from the Baker Lab to design novel proteins that bind to specific dyes created by the Lavis Lab, potentially transforming biological imaging by enabling the observation of numerous proteins at once, a feat not possible with current technologies.
Trendline Trendline
Anixa Biosciences Reports Positive Survival Data in Ovarian Cancer Trial

Anixa Biosciences Reports Positive Survival Data in Ovarian Cancer Trial

Anixa Biosciences Reports Positive Survival Data in Ovarian Cancer Trial